The US Food and Drug Administration approved a lower dose of a previously approved therapy for prostate cancer after reviewing a post-marketing study. READ MORE
Researchers compared the impact of hypofractionated radiation therapy and conventional radiation therapy on quality of life in patients with low-risk prostate cancer.
SBRT for men with prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.
Patients with metastatic castrate resistant prostate cancer treated with enzalutamide may experience central nervous system adverse events.
Active surveillance for patients with low-risk prostate cancer can provide similar quality of life to that of men living without cancer.
The US Food and Drug Administration approved a lower dose of a previously approved therapy for prostate cancer after reviewing a post-marketing study.
Patients with high-risk prostate cancer initiating long-term hormone therapy will likely benefit from two new treatments with comparable efficacy and safety profiles.
Older men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even those who may be too old to benefit from the treatment.
Androgen-deprivation therapy is associated with an increased risk of heart failure in men with localized prostate cancer who have no pre-existing cardiovascular disease.
Research in Review
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts.
A combination regimen plus androgen-deprivation therapy prolongs OS and radiographic PFS in newly diagnosed patients with metastatic, castration-sensitive prostate cancer.
Recent research explored the potential of a subset of patients with intermediate-risk prostate cancer likely to benefit from active surveillance.
Positron emission tomography and computed tomography scans specific to prostate cancer can detect further disease and improve clinical management.